Beil W, Bersimbaev R J, Hannemann H, Sewing K F
Abteilung Allgemeine Pharmakologie, Medizinische Hochschule Hannover, BRD.
Pharmacology. 1990;40(1):8-20. doi: 10.1159/000138633.
The calcium channel antagonists verapamil, gallopamil and nifedipine were tested for their effects on acid secretion stimulated by histamine and dibutyryl-cyclic AMP in isolated and enriched guinea pig parietal cells, on adenylate cyclase activity mediated by histamine H2 receptors, on histamine-stimulated increase in cytosolic-free Ca2+ concentration [Ca2+], on gastric H+/K(+)-ATPase activity and on H+/K(+)-ATPase-mediated proton uptake in intact gastric membrane vesicles. Verapamil and gallopamil impaired all cellular and enzymatic test systems studied. Both drugs affected with highest potency the acid secretion in the parietal cell preparation (IC50: 1-2 mumol/l) and the H+/K(+)-ATPase-mediated H+ uptake in gastric membrane vesicles, whereas their inhibitory action was less pronounced on adenylate cyclase and on histamine-induced increase in cytosolic-free [Ca2+]. The type of interaction found in the gastric membrane vesicle preparation indicates that both drugs act as protonophores. Nifedipine was less effective as an inhibitor of acid secretion in the parietal cell preparation and in reducing proton concentration in isolated gastric membrane vesicles. The drug failed to block adenylate cyclase and H+/K+-ATPase activity. Since nifedipine is a more effective calcium channel blocking agent but a less lipophilic drug than verapamil and gallopamil, we conclude that the antisecretory activity of calcium channel antagonists in vitro is mediated by a nonspecific, i.e. a protonophoric, action. We suggest that verapamil exhibits its antisecretory activity in vivo partially by its protonophoric action at the secretory membrane of the parietal cell, whereas the decrease in acid secretion by nifedipine is not mediated by this mechanism.
对钙通道拮抗剂维拉帕米、加洛帕米和硝苯地平进行了测试,观察它们对以下各项的影响:分离并富集的豚鼠壁细胞中由组胺和二丁酰环磷腺苷刺激的胃酸分泌、组胺H2受体介导的腺苷酸环化酶活性、组胺刺激引起的胞质游离钙浓度[Ca2+]升高、胃H+/K(+)-ATP酶活性以及完整胃膜囊泡中H+/K(+)-ATP酶介导的质子摄取。维拉帕米和加洛帕米损害了所研究的所有细胞和酶测试系统。两种药物对壁细胞制剂中的胃酸分泌(IC50:1 - 2 μmol/L)和胃膜囊泡中H+/K(+)-ATP酶介导的H+摄取影响最大,而它们对腺苷酸环化酶和组胺诱导的胞质游离[Ca2+]升高的抑制作用则较弱。在胃膜囊泡制剂中发现的相互作用类型表明,这两种药物都作为质子载体起作用。硝苯地平在壁细胞制剂中作为胃酸分泌抑制剂以及在降低分离的胃膜囊泡中的质子浓度方面效果较差。该药物未能阻断腺苷酸环化酶和H+/K+-ATP酶活性。由于硝苯地平是一种比维拉帕米和加洛帕米更有效的钙通道阻滞剂,但脂溶性较低,我们得出结论,钙通道拮抗剂在体外的抗分泌活性是由非特异性作用,即质子载体作用介导的。我们认为维拉帕米在体内部分通过其在壁细胞分泌膜上的质子载体作用发挥抗分泌活性,而硝苯地平引起的胃酸分泌减少不是由该机制介导的。